A natural plant compound called atractylodin significantly reduced fatty liver disease in obese mice by helping liver cells break down and burn stored fat more efficiently. According to Gram Research analysis, the compound works by increasing contact between fat droplets and mitochondria (energy-producing structures), which allows cells to access and burn fat more effectively through a specific molecular pathway called the PLIN2-ATGL/CPT1A axis.
Researchers discovered that atractylodin, a natural compound found in a traditional Chinese herb called Atractylodes lancea, may help reverse fatty liver disease caused by obesity. In studies with mice and human liver cells, the compound worked by helping the body break down and burn stored fat in the liver more efficiently. According to Gram Research analysis, this discovery could lead to new natural treatments for fatty liver disease, which affects millions of people worldwide and often develops alongside obesity and diabetes.
Key Statistics
A 2026 research study published in Phytomedicine found that atractylodin, a compound from the herb Atractylodes lancea, significantly reduced fat accumulation in the livers of obese mice and performed comparably to the prescription medication Orlistat.
According to a 2026 cell study, atractylodin increased physical contact between fat droplets and mitochondria, enabling cells to burn fatty acids more efficiently through activation of the PLIN2-ATGL/CPT1A molecular pathway.
A 2026 research analysis showed that atractylodin’s effectiveness in reducing liver fat depends on specific proteins including CPT1A and PLIN2, suggesting the compound works through coordinated regulation of multiple cellular processes.
The Quick Take
- What they studied: Whether a natural plant compound called atractylodin could reduce fat buildup in the liver caused by obesity, and how it works at the cellular level.
- Who participated: The research involved mice fed a high-fat diet for 18 weeks total, plus laboratory studies using human liver cells treated with the compound.
- Key finding: Atractylodin significantly reduced fat accumulation in the liver by helping cells break down stored fat and burn it for energy more efficiently.
- What it means for you: This natural compound shows promise as a potential treatment for fatty liver disease, though human clinical trials are still needed before it can be recommended as a medical treatment.
The Research Details
Scientists conducted a two-part study to understand how atractylodin works against fatty liver disease. First, they fed mice a high-fat diet for 12 weeks to create obesity and fatty liver, then gave some mice atractylodin for 6 weeks while others received a standard obesity medication called Orlistat as a comparison. They measured liver damage, fat content, and changes in liver tissue under a microscope.
Second, the researchers used human liver cells in laboratory dishes, exposing them to excess fatty acids to mimic the fatty liver condition. They then treated these cells with atractylodin and studied what happened at the molecular level—essentially watching how the compound changed the behavior of specific proteins and fat molecules inside cells.
This combination of animal studies and cell studies allowed researchers to see both the real-world effects in a living organism and the detailed molecular mechanisms happening inside individual cells.
This research approach is important because it bridges the gap between basic science and practical medicine. The mouse studies show whether the compound actually works in a living body, while the cell studies reveal the exact biological mechanisms—the ‘how’ behind the ‘what.’ Understanding the mechanism helps scientists predict whether the compound might work in humans and identify potential side effects.
The study used multiple complementary methods to verify findings: tissue examination under microscopes, protein analysis using western blotting, and genetic manipulation to confirm which proteins were responsible for the effects. The researchers also used both mouse models and two different human liver cell lines, which strengthens confidence in the results. However, the study has not yet progressed to human clinical trials, so real-world effectiveness in people remains unknown.
What the Results Show
Atractylodin significantly reduced fat accumulation in the livers of obese mice. When researchers examined liver tissue under a microscope, they found that mice treated with atractylodin had much less fatty buildup compared to untreated obese mice. The compound worked comparably to Orlistat, a prescription weight-loss medication, suggesting it may be an effective alternative.
In human liver cells grown in the laboratory, atractylodin reduced the amount of fat that accumulated when cells were exposed to excess fatty acids. The compound appeared to work by activating two key cellular processes: lipolysis (breaking down stored fat) and fatty acid oxidation (burning fat for energy). Molecular analysis showed that atractylodin reduced levels of a protein called PLIN2, which normally protects fat droplets from being broken down.
Microscopy studies revealed that atractylodin increased physical contact between fat droplets and mitochondria (the cell’s energy-producing structures). This closer interaction appears to be crucial because it allows mitochondria to more efficiently access and burn the fatty acids released from fat droplets. The researchers identified a specific molecular pathway—the PLIN2-ATGL/CPT1A axis—as the mechanism through which atractylodin produces these effects.
The research showed that atractylodin’s effects depend on specific proteins working together. When researchers artificially reduced levels of CPT1A (a protein that transports fatty acids into mitochondria) or overproduced PLIN2 (the fat-protecting protein), atractylodin’s beneficial effects were diminished or blocked. This confirmed that these specific proteins are essential for how the compound works. The findings suggest that atractylodin doesn’t work through a single mechanism but rather by coordinating multiple cellular processes simultaneously.
Previous research had shown that atractylodin has anti-inflammatory and metabolic benefits, but the specific mechanisms for treating fatty liver disease were unclear. This study provides the first detailed explanation of how the compound works at the molecular level. The findings align with emerging research showing that improving communication between fat droplets and mitochondria is a promising strategy for treating metabolic diseases. The compound’s effectiveness compared to Orlistat suggests it may be a viable natural alternative, though direct human comparisons are needed.
This study has several important limitations. First, it was conducted in mice and laboratory cells, not in humans, so results may not directly translate to people. Second, the sample size of mice was not specified in the available information, making it difficult to assess statistical power. Third, the study examined only short-term effects (6 weeks of treatment), so long-term safety and effectiveness remain unknown. Fourth, the research doesn’t address whether atractylodin would work in people with different genetic backgrounds or other medical conditions. Finally, the optimal dose for humans, potential side effects, and interactions with other medications have not been studied.
The Bottom Line
Based on this research, atractylodin shows promise as a potential treatment for obesity-related fatty liver disease, but it is not yet ready for medical use in humans. Current evidence level: Preclinical (animal and cell studies only). Confidence: Moderate for the biological mechanism, but low for human application. Anyone with fatty liver disease should continue following their doctor’s current treatment plan and discuss any interest in atractylodin-based treatments with their healthcare provider once human studies become available.
This research is most relevant to people with obesity-related fatty liver disease, researchers studying metabolic diseases, and pharmaceutical companies developing new treatments. It may also interest people with metabolic syndrome, type 2 diabetes, or cardiovascular disease, as these conditions often accompany fatty liver disease. However, until human clinical trials are completed, this remains a research finding rather than a practical treatment option.
Based on the study timeline, beneficial effects appeared within 6 weeks in mice. However, human studies would likely take 3-5 years to complete, and regulatory approval could add another 1-2 years. Realistically, if atractylodin moves forward in development, it would be 5-10 years before it might become available as a medical treatment.
Frequently Asked Questions
Can I take atractylodin supplements now to treat my fatty liver disease?
Atractylodin is not yet approved as a medical treatment for humans. Current research is limited to animal studies and laboratory cells. Speak with your doctor about proven treatments like weight loss, exercise, and dietary changes, which are currently the most effective approaches for fatty liver disease.
How does atractylodin help the liver burn fat?
Atractylodin reduces a protein called PLIN2 that normally protects stored fat from being broken down. This allows fat droplets to move closer to mitochondria (cellular energy factories), which can then burn the fatty acids for energy more efficiently through a process called fatty acid oxidation.
Is atractylodin better than Orlistat for treating obesity?
In mouse studies, atractylodin performed similarly to Orlistat in reducing liver fat. However, no direct human comparisons have been made. Orlistat is an approved medication, while atractylodin remains experimental. Your doctor can help determine which approach is best for your situation.
When will atractylodin be available as a treatment?
Human clinical trials have not yet begun. If development proceeds, it typically takes 5-10 years from current research to regulatory approval and availability as a medical treatment. Researchers will need to conduct safety and effectiveness studies in people before it can be prescribed.
What should I do now if I have fatty liver disease?
Focus on proven strategies: lose 5-10% of body weight through diet and exercise, reduce saturated fat and processed foods, increase physical activity to at least 150 minutes weekly, and work with your doctor to monitor liver health through blood tests and imaging.
Want to Apply This Research?
- Users interested in fatty liver disease management could track liver health markers: weekly weight, monthly liver enzyme tests (ALT/AST) if available through their doctor, and daily diet quality scores focusing on reducing saturated fat and processed foods.
- The app could recommend evidence-based lifestyle changes that work similarly to atractylodin’s mechanism: increasing aerobic exercise to boost fat burning in mitochondria, reducing high-fat food intake to decrease fat droplet accumulation, and tracking these changes alongside any medical treatments.
- Long-term tracking should include quarterly liver ultrasounds or blood tests (coordinated with healthcare provider), monthly weight measurements, and continuous monitoring of diet and exercise adherence. Users should log any new supplements or medications that might interact with future atractylodin-based treatments.
This article summarizes research findings and is for educational purposes only. Atractylodin is not approved for medical use in humans and should not be used to treat any medical condition without consulting a healthcare provider. The findings are based on animal studies and laboratory research; human safety and effectiveness have not been established. Anyone with fatty liver disease should work with their doctor to develop an appropriate treatment plan based on proven medical approaches. This article does not constitute medical advice, and readers should not make changes to their medical treatment based on this information alone.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.